# BAY43-9006 Phase II Study for Renal Cell Carcinoma

> **NCT00661375** · PHASE2 · COMPLETED · sponsor: **Bayer** · enrollment: 131 (actual)

## Conditions studied

- Carcinoma, Renal Cell

## Interventions

- **DRUG:** Nexavar (Sorafenib, BAY43-9006)

## Key facts

- **NCT ID:** NCT00661375
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-11
- **Primary completion:** 2006-03
- **Final completion:** 2006-03
- **Target enrollment:** 131 (ACTUAL)
- **Last updated:** 2014-12-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00661375

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00661375, "BAY43-9006 Phase II Study for Renal Cell Carcinoma". Retrieved via AI Analytics 2026-08-12 from https://api.ai-analytics.org/clinical/NCT00661375. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*